Ya Zhe Du - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Plos One|July 21, 2025

Hematological malignancy burden in mainland China and Taiwan from 1990 to 2021 and decadal projections: Insights from the global burden of disease study 2021Yu Fu, Ya-Zhe Du, Yun-Wei Zhang, et al.

Zhongguo Shi Yan Xue Ye Xue Za Zhi|March 7, 2014

[Clinical characteristics and therapeutic efficacy of normal karyotype AML patients with CEBPA mutation]Ya-Zhe Du, Long Su, Wei Li, et al.

Annals of Hematology|November 15, 2022

Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemiaYun-Wei Zhang, Long Su, Ye-Hui Tan, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Plos One|July 21, 2025

Hematological malignancy burden in mainland China and Taiwan from 1990 to 2021 and decadal projections: Insights from the global burden of disease study 2021Yu Fu, Ya-Zhe Du, Yun-Wei Zhang, et al.

Zhongguo Shi Yan Xue Ye Xue Za Zhi|March 7, 2014

[Clinical characteristics and therapeutic efficacy of normal karyotype AML patients with CEBPA mutation]Ya-Zhe Du, Long Su, Wei Li, et al.

Annals of Hematology|November 15, 2022

Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemiaYun-Wei Zhang, Long Su, Ye-Hui Tan, et al.

Pageof 1